- Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
- Pharmaceutical Industry Competition Law Training Course (ONLINE EVENT: June 5, 2025)
- Pharmaceuticals and Biotechnology Asset Purchase Agreements Analysis Report 2025 and Directory of Deals Signed by Leading Players Since 2019
- Pharmaceuticals Licensing Deals Trends Report 2025 and Directory of Deals Signed Since 2019
- PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025â„¢ Annual Meeting
- U.S. Plasma Derived Therapies Market Research 2025-2035, Competitive Analysis of BIOLIFE, CSL Behring, Grifols, Octapharma, Kedrion, LFB Group, Emergent BioSolutions, and RAAS Blood Products
- [Latest] Global Extra Virgin Avocado Oil Market Size/Share Worth USD 971.13 Million by 2034 at a 5.13% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
- Al in Biotechnology Markets, 2029: Drug Design & Optimisation, Biomarker, SAR; Clinical Trial Design, RWE, Inventory, Supply Chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events
- China Pharmaceutical Directory 2025 – The Ultimate Guide to China's Pharma & Biotech Industry
- BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
